MASAYORI HAGIMORI

Prof. Dr. MASAYORI HAGIMORI

Mukogawa Women’s University

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2018 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
TSTadaharu Suga
Tadaharu Suga
NKNaoya Kato
Naoya Kato
MHMASAYORI HAGIMORI
MASAYORI HAGIMORI
YFYuki Fuchigami
Yuki Fuchigami
NKNaotaka Kuroda
Naotaka Kuroda
SKShigeru Kawakami
Shigeru Kawakami

1 October 2018 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
MHMASAYORI HAGIMORI
MASAYORI HAGIMORI
YCYorinao Chinda
Yorinao Chinda
TSTadaharu Suga
Tadaharu Suga
KYKazuto Yamanami
Kazuto Yamanami
NKNaoya Kato
Naoya Kato
SKShigeru Kawakami
Shigeru Kawakami
The mannose receptor, which is responsible for tumor invasion, proliferation, and metastasis in the tumor microenvironment, is overexpressed in tumor-associated macrophages. Mannose is commonly applied to PEGylated liposomes in macrophage-targeted cancer therapy. To develop a high functionality and quality (HFQ) lipid for macrophage-targeted liposomes, we designed a novel mannosylated lipid with improved mannose receptor binding affinity using serine-glycine repeats (SG)n. We synthesized Man(S)-(SG)5-SSK-K(Pal)2 using only a fluorenylmethyloxycarbonyl (Fmoc) protecting group solid-phase peptide synthesis method, which produced a high-quality lipid at a moderately good yield. We then prepared Man-(SG)5/PEGylated liposomes using a post-insertion technique to insert Man(S)-(SG)5-SSK-K(Pal)2 into the PEGylated liposomes. In vitro cell investigations revealed that the Man-(SG)5/PEGylated liposomes effectively associated with mouse peritoneal macrophages by interacting with the mannose receptors. The results suggest that we produced a novel high-quality, highly functional mannosylated lipid that is suitable for clinical drug delivery applications.

1 April 2019 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
KOKoki Ogawa
Koki Ogawa
YFYuki Fuchigami
Yuki Fuchigami
MHMASAYORI HAGIMORI
MASAYORI HAGIMORI
SFShintaro Fumoto
Shintaro Fumoto
KMKazuo Maruyama
Kazuo Maruyama
SKShigeru Kawakami
Shigeru Kawakami

22 May 2019 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
NKNishimura Koyo
Nishimura Koyo
KYKeita Yonezawa
Keita Yonezawa
SFShintaro Fumoto
Shintaro Fumoto
YMYusuke Miura
Yusuke Miura
MHMASAYORI HAGIMORI
MASAYORI HAGIMORI
SKShigeru Kawakami
Shigeru Kawakami
In the present study, we developed a sonoporation system, namely “direct sonoporation”, for transfecting the peritoneum from a defined surface area to avoid systematic side effects. Here, the transfection characteristics are explained because there is less information about direct sonoporation. Naked pDNA and nanobubbles were administered to diffusion cell attached to the visceral and parietal peritoneum from the liver and peritoneal wall surface, respectively. Then, ultrasound was irradiated. Direct sonoporation showed a higher transfection efficacy at the applied peritoneum site from the liver surface while other sites were not detected. Moreover, transgene expression was observed in the peritoneal mesothelial cells (PMCs) at the applied peritoneum site. No abnormality was observed in the inner part of the liver. Although transgene expression of the visceral peritoneum was tenfold higher than that of the parietal peritoneum, transgene expression was observed in the PMCs on both the applied peritoneum sites. These results suggest that direct sonoporation is a site-specific transfection method of the PMCs on the applied peritoneum site without transgene expression at other sites and show little toxicity in the inner tissues at the applied site via cavitation energy. This information is valuable for the development of an intraperitoneal sonoporation device for treatment of peritoneal diseases such as peritoneal fibrosis.

2 May 2019 in Sensors
Verified
Journal Article
Open access
PDF file
MHMASAYORI HAGIMORI
MASAYORI HAGIMORI
MTMana Taniura
Mana Taniura
NMNaoko Mizuyama
Naoko Mizuyama
YKYasushi Karimine
Yasushi Karimine
SKShigeru Kawakami
Shigeru Kawakami
TMTakahiro Mukai
Takahiro Mukai
A small extent of endogenous labile zinc is involved in many vital physiological roles in living systems. However, its detailed functions have not been fully elucidated. In this study, we developed a novel biheteroaryl-based low molecular weight fluorescent sensor, 3-(phenylsulfonyl)-pyrazine–pyridone (5b), and applied it for the detection of endogenous labile zinc ions from lung cancer cells during apoptosis. The electron-withdrawing property of the sulfonyl group between the phenyl ring as an electron donor and the pyridone ring as a fluorophore inhibited the intramolecular charge transfer state, and the background fluorescence of the sensor was decreased in aqueous media. From the structure–fluorescence relationship analysis of the substituent effects with/without Zn2+, compound 5b acting as a sensor possessed favorable properties, including a longer emission wavelength, a large Stokes shift (over 100 nm), a large fluorescence enhancement in response to Zn2+ under physical conditions, and good cell membrane permeability in living cells. Fluorescence imaging studies of human lung adenocarcinoma cells (A549) undergoing apoptosis revealed that compound 5b could detect endogenous labile zinc ions. These experiments suggested that the low molecular weight compound 5b is a potential fluorescence sensor for Zn2+ toward understanding its functions in living systems.